Helga Hummel

Development of a multilevel approach for the evaluation of nanomaterials’ toxicity

AIM To develop a multilevel approach that includes different toxicity tests and gene-expression studies for toxicity evaluation of engineered nanomaterials developed for biomedical applications. MATERIALS & METHODS K-562, MCF-7 and U-937 human-derived cell lines were used as models for in vitro toxicity tests. These tests included viability assays (3-[4,5-dimethylthiazol-2-yl]-5-[3-carboxymethoxyphenyl]-2-[4-sulfophenyl]-2H-tetrazolium [MTS] assay); evaluation of apoptosis/necrosis by propidium iodide staining and DNA laddering assay; evaluation of mitochondrial toxicity (5,5´,6,6´-tetrachloro-1,1´,3,3´-tetraethyl-benzimidazolcarbocyanine iodide [JC-1] assay); transmission electron microscopy analysis and gene expression analysis by DNA microarray. For in vivo toxicity evaluation, Swiss mice were used for monitoring acute or chronic effects. Two superparamagnetic contrast agents approved for human use (Resovist and Primovist) and two new lanthanide-based luminescent nanoparticles were tested. RESULTS & DISCUSSION The nanomaterials approved for human use did not show significant toxicities in our assays. Toxicity studies performed on lanthanide-based nanoparticles (EDTA120 and EDTA120D) complexed with the chelating agent EDTA revealed that these nanomaterials induced necrosis in U-937 and K-562 cells while no toxicity was observed in MCF-7 cells. Moreover, no in vivo effects have been observed. The comparative analysis of the nanomaterials and their separated components showed that the toxicity in U-937 and K-562 cells was mainly due to the presence of EDTA. CONCLUSION The multilevel approach proved to be useful for nanomaterial toxicity characterization. In particular, for the lanthanide-based nanoparticles tested in this work, the EDTA was identified as the main cause of the toxicity in vitro, suggesting a possible applicability of these nanoparticle suspensions for in vivo optical imaging.

Near-infrared luminescent nanomaterials for in-vivo optical imaging

Optical imaging using unspecific contrast agents as well as targeted and disease-specific agents play a vital role in preclinical research. Moreover, optical imaging is on the verge of establishing itself as a clinically relevant imaging modality. Also in-vitro diagnostical procedures rely to a large degree on optical labels to report disease-specific events. Materials that fulfill the basic requirements of this market are being used today, with cyanine dyes and semiconductor quantum dots being excellent examples. Other materials are being tested in laboratories throughout the world. Design rules suitable to develop new optical labels for in-vivo near-infrared optical imaging procedures have been formulated by us, and we have developed synthesis routes that lead to nano particles with small diameter, narrow size distribution, high quantum yield, and with stable surfaces required for bioconjugation to disease-specific ligands.

Labeling of Anti-MUC-1 Binding Single Chain Fv Fragments to Surface Modified Upconversion Nanoparticles for an Initial in Vivo Molecular Imaging Proof of Principle Approach

In vivo optical Imaging is an inexpensive and highly sensitive modality to investigate and follow up diseases like breast cancer. However, fluorescence labels and specific tracers are still works in progress to bring this promising modality into the clinical day-to-day use. In this study an anti-MUC-1 binding single-chain antibody fragment was screened, produced and afterwards labeled with newly designed and surface modified NaYF4:Yb,Er upconversion nanoparticles as fluorescence reporter constructs. The MUC-1 binding of the conjugate was examined in vitro and in vivo using modified state-of-the-art small animal Imaging equipment. Binding of the newly generated upconversion nanoparticle based probe to MUC-1 positive cells was clearly shown via laser scanning microscopy and in an initial proof of principal small animal optical imaging approach.

Formation of blade and slot die coated small molecule multilayers for OLED applications studied theoretically and by XPS depth profiling

Slot die coaters especially designed for low material consumption and doctor blades were used to process small molecule solutions for organic light-emitting diodes (OLEDs). Optimum process parameters were developed for the large-scale coating techniques to generate stable single and multiple layers only a few nanometers thick. Achieving a multilayer architecture for solution-processed OLEDs is the most challenging step. X-ray photoelectron spectroscopy sputter depth profiling was performed to determine defined interfaces between coated organic layers. Commercially available small molecules NPB (N,N’-Di(1-naphthyl)-N,N’-diphenyl-(1,1’-biphenyl)-4,4’-diamine) and BAlq (Bis(8-hdroxy-2methylquinoline)-(4-phenylphenoxy)aluminum), originally developed for vacuum deposition, were used as hole, respectively electron transport material. Defined double-layers were processed with both scalable coating methods using the orthogonal solvent approach. The use of non-orthogonal solvents resulted in complete intermixing of the material. The results are explained by calculations of solubilities and simulating drying and diffusion kinetics of the small molecule solutions.

Luminescent Nanoparticles for Molecular Medicine

Novel optical labels based on nanophosphor materials like LaPO4:Ce,Tb and CePO4:Tb-LaPO4 core-shell nanophosphors were presented. Core particles could be synthesised smaller than 10nm and stabilized in aqueous media. Polymer coatings of individual nanoparticles increased long term stability and introduced functional groups of interest for bioconjugation chemistry. A new strategy for conjugation of bioligands via His-tags was given. In feasibility studies for in-vitro diagnostic applications these dnanophosphors featured their advantage over organic dyes. As an example the detection of hybridization and thermal induced denaturation events of DNA strands read out by FRET processes was presented.